
Monterosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases including oncology, autoimmune, and inflammatory conditions. Utilizing the QuEEN™ discovery engine, which integrates AI-guided chemistry, structural biology, and proteomics, Monterosa identifies and designs MGDs with unparalleled selectivity, enabling access to a diverse range of validated therapeutic targets. The company boasts an industry-leading pipeline of MGDs, positioning it as a pioneer in precision medicine.
The Director, New Product Planning will play a strategic leadership role in shaping the commercial success of Monte Rosa's emerging pipeline. This individual will direct global commercial assessments, forecast development, and go-to-market planning for new therapeutic candidates.
Monterosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases including oncology, autoimmune, and inflammatory conditions. Utilizing the QuEEN™ discovery engine, which integrates AI-guided chemistry, structural biology, and proteomics, Monterosa identifies and designs MGDs with unparalleled selectivity, enabling access to a diverse range of validated therapeutic targets. The company boasts an industry-leading pipeline of MGDs, positioning it as a pioneer in precision medicine.
Monterosa